Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial) - Top-Institutions - MDSpire

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)

  • By

  • Xiaojing Chen

  • Lixin Liu

  • Xitong Jin

  • Yanan Cheng

  • Huanwen Wu

  • Yan You

  • Yuligh Liou

  • Pei Liu

  • Jinghe Lang

  • Lei Li

  • June 19, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Peking Union Medical College Hospital
    Peking Union Medical College Hospital

    Beijing, China

    Key Differentiators

    • Gynecology
    • Oncology

  • #2

    University College London
    University College London

    London, United Kingdom

    Key Differentiators

    • Gynecology
    • Oncology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Gynecology
    • Oncology

Original Source(s)

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)

  • by Xiaojing Chen, Lixin Liu, Xitong Jin, Yanan Cheng, Huanwen Wu, Yan You, Yuligh Liou, Pei Liu, Jinghe Lang, Lei Li

  • June 19, 2026

Related Content

PRDM1-mediated epigenetic and transcriptional repression mechanisms: a key hub in immune differentiation, tumor progression, and inflammatory responses

Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making

2026 AACR Prostate Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min